PBYIPUMA BIOTECHNOLOGY, INC.
Pharmaceutical Preparations
- Revenue
- $228M
- 0.9% YoY
- Operating margin
- 16.3%
- 22% YoY
- EBITDA
- $48M
- 14% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.5×
- −$25M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear134% of net incomeCash flow under 80% of net income
- Dilutive SBCClear3% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $253M | $228M | $236M | $230M | $228M | 0.9% |
| Operating income | $1M | $24M | $33M | $31M | $37M | 20% |
| Net income | $29M | $2K | $22M | $30M | $31M | 2.8% |
| Operating cash flow | $21M | −$16M | $27M | $39M | $42M | 7.4% |
| Capex | $0 | $0 | $140K | $56K | $71K | 27% |
| Stock-based comp | $33M | $12M | $10M | $8M | $7M | 16% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $612K · 2
- Net
- −$612K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $4M | 58 | 125 |
| FY2024 | $4M | $3M | 30 | 93 |
| FY2023 | $3M | $3M | 42 | 94 |
| FY2022 | $3M | $3M | 41 | 90 |
| FY2021 | $18M | $15M | 30 | 100 |